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Abstract
Summary Vertebral fracture assessment (VFA) is a new
method for imaging thoracolumbar spine on bone densi-
tometer. Among patients referred for bone densitometry, the
selection of patients for VFA testing can be optimized using
an index derived from clinical risk factors and bone density
measurement.
Purpose VFA, a method for imaging thoracolumbar spine
on bone densitometer, was developed because vertebral
fractures, although common and predictive of future
fractures, are often not clinically diagnosed. The study
objective was to develop a strategy for selecting patients for
VFA.
Methods A convenience sample from a university hospital
bone densitometry center included 892 subjects (795
women) referred for bone mineral density (BMD) testing.
We used questionnaires to capture clinical risk factors and
dual-energy X-ray absorptiometry to obtain BMD and VFA.
Results Prevalence of vertebral fractures was 18% in
women and 31% in men (p=0.003 for gender difference).
In women, age, height loss, glucocorticoid use, history of
vertebral and other fractures, and BMD T-score were
significantly and independently associated with vertebral
fractures. A multivariate model which included above
predictors had an area under the receiver operating curve
of 0.85 with 95% confidence interval (CI) of 0.81 to 0.89.
A risk factor index was derived from the above multivariate
model. Using a level of 2 as a cut-off yielded 93%
sensitivity (95% CI 87, 96) and 48% specificity (95% CI
69, 83). Assuming a 15% prevalence of vertebral fractures,
this cut-off value had a 24% positive and 97% negative
predictive value and required VFA scanning of three
women at a cost of $60 (assuming a $20 cost/VFA scan)
to detect one with vertebral fracture(s).
Conclusions Selecting patients for VFA can be optimized
using an index derived from BMD measurement and easily
obtained clinical risk factors.
Keywords Bonedensitometry.FRAX.Osteoporosis.
Vertebralfractures.VFA
Introduction
Vertebral fractures are the most common osteoporotic
fractures. They are important to detect because they are
associated with significant morbidity, mortality, and re-
duced quality of life [1–3], and because they strongly
predict future fractures [4–7]. Furthermore, the increase in
fracture risk associated with vertebral fractures is indepen-
dent of, and additive to, bone mineral density (BMD)
measurement [7–9]. Therefore, having information about
vertebral fractures in conjunction with BMD allows
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ate therapies. Because only one third of vertebral fractures
found on radiographs are clinically diagnosed [10–12],
imaging is necessary for their detection. This has required
radiographs which are usually not obtained in the course of
clinical evaluation of osteoporosis. Further, even when
vertebral fractures are present on radiographs, they are often
not recognized by the reporting radiologist and do not lead
to the diagnosis and appropriate treatment of osteoporosis
[12, 13]. Recognition of the importance of vertebral
fractures for osteoporosis care, coupled with the realization
that they are often not clinically apparent, has led to the
development of vertebral fracture assessment (VFA). VFA
is a method for imaging the thoracolumbar spine on bone
densitometers, usually obtained at the time of BMD
measurement. This rapid and simple procedure is associated
with low cost and radiation exposure, and has a reasonably
good ability to detect vertebral fractures (reviewed in [14]).
However, it is not clear how to best select patients for
VFA imaging, maximizing the detection of vertebral
fractures yet minimizing scanning of subjects in whom
finding a fracture is unlikely. The International Society for
Clinical Densitometry (ISCD) has formulated recommen-
dations for selecting patients for VFA [14], though such
recommendations have not been tested in practice. There-
fore, we set out to determine which patients among those
who present for BMD measurement should have VFA
imaging. We postulated that the information needed for
decision making should be easily obtained through a short
interview or intake questionnaire to permit its eventual use
in a busy densitometry practice. We included risk factors
such as age, history of fractures, and height loss, which
were found in population studies to best identify subjects
with vertebral fractures on radiographs [15, 16]. We also
added the results of BMD measurement, since it is readily
available at the time of VFA testing, and the history of
glucocorticoid use, which is associated with increased risk
of vertebral fractures [17–19] and is a common indication
for BMD testing.
Methods
Study subjects The study was approved by the University
of Chicago’s Institutional Review Board and all participants
signed a written informed consent. A convenience sample
included 974 subjects (869 women) recruited when they
presented for BMD measurement as part of their clinical
care between 2001 and 2007. The densitometry facility
performs all BMD testing at the University of Chicago, and
patients are referred mostly by University of Chicago
faculty. The patients come from the geographic area around
the campus to receive their primary care at the University of
Chicago or from the Metropolitan Chicago Area and
Northwest Indiana for tertiary care. It is not known which
of the study subjects, or densitometry patients in general,
belong to which of these groups, as they cannot be strictly
defined by geography. There were no specific criteria for
including patients in the study—it required that the study
personnel be present and that the subjects consent to
participate.
Procedures The subjects completed a questionnaire which
included information on personal and family history of
fractures and their circumstances, young adult height and
weight, medical history, medication use, and personal
habits such as smoking, alcohol consumption, calcium
intake, and activity level. Height and weight were measured
using standard clinic equipment. Using this information, we
also calculated the 10-year probability of major osteopo-
rotic fractures using the version 3 of FRAX
® web-based
tool [20].
VFA images and BMD measurements of the lumbar
spine and proximal femur were obtained by two ISCD-
certified technologists using a Prodigy densitometer (GE
Medical Systems, Madison, WI, USA). All VFA images
were evaluated by one ISCD-trained clinician (TJV) using
Genant semi-quantitative approach [21] as recommended
by the ISCD [14, 22] where vertebra with a fracture on
visual inspections is assigned the following grades: grade 1
(mild) fracture represents a reduction in vertebral height of
20–25%; grade 2 (moderate) a reduction of 26–40%; and
grade 3 (severe) a reduction of over 40%. A subject in the
vertebral fracture group had at least one grade 2 fracture or
two grade 1 fractures. The main analysis was performed
after excluding subjects with a single grade 1 fracture (N=
31) because it is often not clear whether these represent true
fractures or non-fracture deformities, because grade 1
fractures are not as clearly predictive of future fractures as
are higher grades [23], and because they are often difficult
to conclusively diagnose on VFA [14, 22, 24].
Definition of risk factors used in analysis Height loss was
calculated by subtracting the measured height from the self-
reported young adult height. Self-reported vertebral frac-
tures were present if the subject reported spine or vertebral
fractures (excluding neck or cervical fractures) in response
to the question “have you had any broken bones”. Non-
vertebral (peripheral) fracture was defined as any fracture
occurring after age 25, in the course of usual physical
activity, excluding fractures of the face, fingers, and toes, or
those resulting from a motor vehicle accident. Glucocorti-
2084 Osteoporos Int (2010) 21:2083–2091coid use (systemic but not inhaled) was defined as at least
5 mg/day of prednisone or equivalent for at least 3 months
(cumulative exposure equivalent to at least 0.450 g of
prednisone), as recommended by the American College of
Rheumatology [25]. For BMD measurement, the lower
of the lumbar spine or proximal femur T-score (femoral
neck or total hip) was used for analysis as recommended by
the ISCD [26].
Statistical analysis All analyses were performed using
STATA statistical software package [27]. The differences
in the clinical characteristics and risk factors between men
and women and between subjects with and without
vertebral fractures were compared using t tests for
continuous variables and chi-square tests for categorical
variables. The association between vertebral fracture and
risk factors was modeled using logistic regression. Given
the known gender differences in prevalence of and risk
factors for vertebral fractures, all analyses were a priori
stratified by gender. For 173 subjects who did not provide
information on young adult height, height loss was imputed
via multiple imputation [28] using linear regression
estimates based on measured current height, age, race, and
gender. Standard errors for model estimates accounted for
multiple imputation of height loss [28]. While an increase
in precision was observed using the imputed data (more
narrow confidence intervals), no substantial differences in
the estimates associated with modeled covariates were
observed (i.e., the odds ratios, OR, for each predictor were
not different with or without imputed values). Prediction
models for fracture risk were constructed utilizing data on a
random sample consisting of two thirds of the original
study cohort. Goodness-of-fit tests for predictive models
were carried out using the Hosmer–Lemeshow goodness-
of-fit statistic for binary regression [29]. Out-of-sample
performance of the resulting predictive models was
assessed using the remaining one third of the originally
study cohort as a validation sample.
Results
Among the 974 subjects who consented to participate in the
study, 51 were excluded from analysis because they had un-
interpretable VFAs, and 31 because they had a single grade
1 fracture, leaving 892 (795 women) subjects for analysis.
(Including patients with grade 1 fractures in the fracture
group resulted in qualitatively similar conclusions but
lower strength of association between vertebral fractures
and risk factors.) The clinical characteristics of the
participants are shown in Table 1. Women with and without
fractures were significantly different in all of the risk factors
of interest (Table 1). A higher percentage of women
with fractures were receiving pharmacologic therapy for
osteoporosis, although this difference was not significant
when controlling for presence of osteoporosis by BMD
criteria.
Results for women
Association of vertebral fractures with risk factors
Age was a significant predictor of vertebral fractures alone
and when controlled for BMD T-score (Table 2). The
prevalence of vertebral fractures did not increase until age
60 (Fig. 1a) but then approximately doubled with each
decade, with a progressive increase in probability of fracture
with increasing age (Table 3). Based on this observation, the
variable we used was “age over 50”. BMD T-score was a
significant predictor of fractures with approximate doubling
of the probability of having vertebral fractures for each 1 unit
decrease in the T-score, particularly below −2( F i g .1b,
Tables 2 and 3). The association of vertebral fractures with
BMD was diminished but not eliminated when age was
added to the model (Table 2). Compared to those with
normal BMD, the risk of having vertebral fractures was
significantly higher in women with osteoporosis but not in
those with osteopenia (Table 3), with the probability of
fracture approximately doubling for 1 unit decrease in T-
score below −2( F i g .1b and Table 3). Height loss was also
associated with vertebral fractures (Table 2) even when
controlling for age and BMD, with prevalence of vertebral
fractures doubling for each inch of height loss above 1 in.
(Fig. 1c and Table 3). Use of glucocorticoids was a
significant predictor of vertebral fractures with the strength
of association increasing when age was added in the model
(Table 2).
Combinations of risk factors When combined in a
multivariate regression analysis, all of the risk factors
were still significantly associated with prevalent verte-
bral fractures (Table 2). Based on the area under the
receiver operating characteristic curve (ROC curve;
0.850), the combination of risk factors predicted the
presence of vertebral fractures better than any individual
factor. There were no significant interactions between the
predictors and no significant effect of, or interactions with,
body weight, race, calcium intake, self-reported physical
activity, and use of estrogen, tobacco, or alcohol (data not
shown).
The additive effect of multiple risk factors was captured
by “risk factor index” (RFI) calculated using the regression
Osteoporos Int (2010) 21:2083–2091 2085coefficients derived from the multivariate regression anal-
ysis from Table 2:
RFI ¼ 0:75   ageðdecade over 50Þ 0:26   T
  scoreðlowest of hip and spineÞþ0:24   inch of height loss
þ 0:99ðif history of glucocorticoids useÞþ0:85ðif history of
non vertebral fractureÞþ4ðif self reported history of
vertebral fractureÞ
The RFI predicted the presence of fractures well as
evidenced by the Hosmer–Lemeshow goodness-of-fit test
(χ
2=1.09, p value=0.78). We also considered the perfor-
mance of the index developed on the random sample of two
thirds of the study population on the remaining one third of
subjects in our validation dataset. The area under the ROC
for predicting the presence of vertebral fracture via the RFI
was 0.745 in the remaining one third of subjects in whom
the model was tested. RFI performed better in subjects who
were receiving therapy for osteoporosis than in untreated
patients as evidenced by a higher area under the ROC curve
of 0.900 [95% confidence interval (CI) of 0.860, 0.940] vs.
0.790 (0.733, 0.846).
The prevalence of vertebral fractures according to
different levels of RFI is shown in Fig. 1d. In our study
sample which had 18.4% prevalence of vertebral fractures,
choosing an index ≥2 as a cut-off point resulted in the
optimal ratio of sensitivity to specificity (Table 4). With
index level of ≥3 as a cut-off, the specificity was higher but
the sensitivity was unacceptably low. Table 4 shows the
performance of different levels of index at different
prevalence of vertebral fractures. For example, vertebral
fractures prevalence of 15%, having an index ≥2, has a
positive predictive value of 24%, while the index <2 has
negative predictive value of 97%. In other words, while the
(pre-test) odds of having vertebral fracture(s) is 0.18 for all
subjects, a subject with an index ≥2 has the (post-test) odds
of having vertebral fracture of 0.32 [post-test odds (+) in
Table 4]. In contrast, a subject with an index <2 has odds of
having fracture(s) of only 0.028 [post-test odds (−)i n
Table 4]. If all subjects were to have VFA scan, the number
needed to scan and cost of VFA scanning (assuming $20/
scan) needed to find one subject with vertebral fracture
would be six subjects and $120. Scanning only subjects
Table 1 Clinical characteristics of women and men with and without vertebral fractures
Women (n=795) Men (n=97)
Vertebral fractures Vertebral fractures
Characteristic No Yes p value
a No Yes p value
a
(n=649) (n=146) (n=67) (n=30)
Age, years 61.2 (19–92) 70.5 (20–95) <0.0001 58.1 (20–90) 63.1 (34–87) 0.15
Race
African 210 (81%) 49 (19%) 0.21 16 (73%) 6 (27%) 0.42
Caucasian 398 (82%) 88 (18%) 48 (69%) 22 (31%)
Hispanic 12 (67%) 6 (33%) 1 (33%) 2 (67%)
Asian 29 (91%) 3 (9%) 2 (100%) 0 (0%)
BMD T-score
b −2.2 (−6 to 2.1) −3.0 (−5.2 to 0) <0.0001 −2.1 (−3.9 to 0.9) −3.0 (−5.2 to −0.5) 0.0001
Lumbar spine −1.5 (−5.3 to 3.2) −2.1 (−5.2 to 2.4) <0.0001 −1.2 (−3.9 to 2.6) −2.5 (−5.2 to 2.1) 0.0002
Femoral neck −2.0 (−6.0 to 2.3) −2.7 (−4.9 to 0.3) <0.0001 −1.8 (−3.5 to 2.2) −2.5 (−4.2 to −0.3) 0.002
Total hip −1.4 (−5.3 to 3.1) −2.2 (4.6 to 0.7) <0.0001 −2.3 (−4.3 to −0.3) −2.3 (−4.3 to −0.3) 0.001
Heel −0.8 (−4 to 4.5) −1.5 (−4.1 to 1.7) <0.0001 −1.1 (−4.2 to 2.8) −1.9 (−4.8 to 2.1) 0.018
Height loss, inches 0.9 (0–7) 2.0 (0–7) <0.0001 1.3 (0–6) 1.9 (0–7) 0.04
Non-vertebral fractures 143 (22%) 63 (45%) <0.001 14 (22%) 4 (13%) 0.34
Self-reported vertebral fractures 5 (0.8%) 35 (24%) <0.001 0 (0.0%) 7 (23%) <0.001
Glucocorticoid use 99 (15%) 40 (27%) <0.001 27 (40%) 10 (33%) 0.51
Height, inches 63.3 (51–73) 61.6 (53–69) <0.001 68.5 (62–74) 67.4 (61–74) 0.15
Weight, pounds 152 (74–300) 145 (80–255) 0.025 181 (119–284) 171 (112–283) 0.22
Osteoporosis therapy 235 (36%) 70 (48%) 0.008 21 (31%) 10 (33%) 0.85
Results are given as mean (range) for continuous variables and number (%) for categorical variables
ap values were derived from t test for continuous variables and chi-square test for categorical variables
bLowest of lumbar spine, femoral neck, or total hip T-score
2086 Osteoporos Int (2010) 21:2083–2091with RFI ≥2 would decrease these figures by 50% (three
subjects and $60).
Association of vertebral fractures with FRAX
® In 744
women who were over 40 (which permitted FRAX
calculation), there was a significant (p<0.001) association
between 10-year probability of major osteoporotic fractures
(FRAX_MO) and prevalent vertebral fractures (Table 2),
although the area under the ROC curve was significantly
(p<0.0001) lower than that resulting from RFI model
(Table 2). Using different levels of FRAX_MO as a cut-off
point for detection of prevalent vertebral fractures, the
sensitivity and specificity were 75% (95% CI 68, 82) and
63% (60, 67) for FRAX_MO of 10%, and 59% (51, 67)
and 80% (77, 82) for FRAX_MO of 15%. Lower levels of
FRAX_MO had higher sensitivity but lower specificity: for
FRAX_MO of 7%, the sensitivity and specificity were 85%
(79, 91) and 44% (40, 48) and for FRAX_MO of 5% they
were 92% (87, 96) and 28% (24, 31). Although FRAX is
meant to be applied to untreated patients, we found that the
prediction of vertebral fractures by FRAX was if anything
higher in the treated patients [ROC of 0.776 (0.711, 0.842)]
than in untreated patients [0.721 (0.655, 0.786)].
Results for men
The prevalence of vertebral fractures was significantly higher
in men than in women (31% vs. 18%, p=0.003). Men with
Table 2 Association of risk factors and prevalent vertebral fractures in women, expressed as odds ratio of having a fracture, derived from logistic
regression with presence of vertebral fractures as a binary outcome and each risk factor alone or when controlled for other risk factors, all risk
factors combined, or FRAX
OR (95% CI) p value ROC (95% CI)
Individual risk factors
Age/decade 1.9 (1.6, 2.2) <0.001
Age/decade over 50 2.1 (1.8, 2.6) <0.001 0.719 (0.67, 0.76)
Age over 50 controlled for BMD 1.9 (1.5, 2.3) <0.001
BMD T-score/1 unit decrease 1.9 (1.6, 2.3) <0.001 0.679 (0.63, 0.73)
Controlled for age over 50 1.6 (1.3, 1.9) <0.001
Height loss/1 in. 1.7 (1.5, 1.9) <0.001 0.689 (0.64, 0.74)
Controlled for age over 50 1.4 (1.2, 1.6) <0.001
Controlled for BMD 1.6 (1.4, 1.8) <0.001
Controlled for age over 50 and BMD 1.4 (1.2, 1.6) <0.001
Glucocorticoid use 2.1 (1.3, 2.7) 0.001 0.561 (0.52, 0.60)
Controlled for age over 50 3.2 (2.0, 5.1) <0.001
Controlled for BMD 2.1 (1.3, 3.2) 0.001
Controlled for age over 50 and BMD 3.0 (1.9, 4.8) <0.001
Non-vertebral fracture 2.8 (1.9, 4.1) <0.001 0.612 (0.57, 0.66)
Controlled for age over 50 2.5 (1.6, 3.7) <0.001
Controlled for BMD 2.2 (1.5, 3.3) <0.001
Controlled for age over 50 and BMD 2.2 (1.4, 3.3) <0.001
Self-reported vertebral fracture 41 (16, 106) <0.001 0.616 (0.58, 0.65)
Controlled for age over 50 65 (23, 183) <0.001
Controlled for BMD 37 (14, 99) <0.001
Controlled for age over 50 and BMD 59 (21, 168) <0.001
Combined risk factors
Age/decade over 50 2.1 (1.7, 2.7) <0.001 9
> > > > > > =
> > > > > > ;
0:850 0:81;0:89 ðÞ
T-score/1 unit decrease 1.3 (1.0, 1.6) 0.027
Height loss/1 in. 1.3 (1.1, 1.5) 0.005
Glucocorticoid use 2.7 (1.5, 4.7) <0.001
Non-vertebral fracture 2.4 (1.5, 3.7) <0.001
Self-reported vertebral fracture 55 (19, 164) <0.001
FRAX
10% increase in 10-year probability of major osteoporotic fracture 2.4 (1.9, 2.9) <0.001 0.722 (0.67, 0.77)
OR odds ratio, 95% CI 95% confidence interval, ROC area under the receiver operating characteristic curve, BMD bone mineral density
Osteoporos Int (2010) 21:2083–2091 2087vertebral fractures were younger than women (63.1±2.3 vs.
70.5±1.1, p=0.006), and had lower prevalence of non-
vertebral fractures (13% vs. 45%, p=0.001), but did not
differ in other predictors. Among men, only BMD was
predictive of vertebral fracture in a logistic regression
analysis, with an OR of 2.7 (95% CI=1.6, 2.8) per each
unit decrease in the T-score and area under the ROC curve of
0.738. While height loss was also associated with vertebral
fractures (OR of 1.4 per 1 in. of height loss, p=0.05), this
association was not significant when controlled for BMD.
Discussion
Using data from 795 women referred for BMD measure-
ment at a university hospital, we developed a simple
decision-making tool which incorporates clinical risk
factors and BMD results to identify patients who should
undergo VFA during their densitometry visit. Currently, the
approach to bone densitometry is changing so that, at least
in some regions of the world, treatment decisions will rely
not on BMD alone but on absolute fracture risk calculated
from BMD and clinical risk factors using a FRAX
®
(Fracture Risk Assessment) tool [20], introduced in 2008
by the World Health Organization (WHO) and endorsed by
the National Osteoporosis Foundation [30]. Among the risk
factors used for our VFA decision tool, age, BMD T-score,
history of fracture, and glucocorticoid use will already be
obtained for FRAX calculation. Thus, the patients will need
to answer only two additional questions: young adult height
(to calculate height loss) and history of vertebral (spine)
fractures.
The risk factors included in our model are similar to
those suggested by Vogt [15] and Kaptoge [16]f o r
selecting subjects from a general population for spine
radiography for the purpose of detecting vertebral fractures.
Our model differs from the other two in that it incorporates
BMD results, which are readily available during densitom-
etry visit, and glucocorticoid use, which is a common
indication for densitometry and is strongly associated with
vertebral fractures both in our study (Table 2) and in studies
of glucocorticoid-treated patients [17, 19]. Inclusion of
glucocorticoid use in our model is supported by our
observation that even when controlling for other risk
factors, use of glucocorticoids still confers a two to three
times higher risk of having vertebral fractures (Table 2).
We also compared the results of our model to the ISCD
2007 official position on indications for VFA [14, 31]. In our
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Fig. 1 Prevalence of vertebral fractures relative to a age, b BMD T-score, c height loss, and d level of RFI. n number of women in each strata
2088 Osteoporos Int (2010) 21:2083–2091study population, the RFI ≥2, which we propose as a cut-off
for prompting VFA, provides similar sensitivity and speci-
ficity as the ISCD official position (data not shown). The
advantage of our model, however, is that it incorporates
multiple risk factors in the same model and includes them as
continuous variables instead of selecting pre-defined cut-off
points to be used as an indication. This allows the model to
capture the additive effects of several risk factors and to
detect the increase in probability of fracture along the
continuum of values of the predictors (Fig. 1a–c). For
example, the full gradation of increase in fracture risk
associated with decreasing BMD T-score was lost by
stratifying this continuous variable into the three WHO
diagnostic categories of normal BMD, osteopenia, and
osteoporosis (Table 3). Using FRAX
® to select patients for
VFA also had reasonable sensitivity and specificity albeit not
as good as our RFI. The advantage of our model, in addition
to its better performance, is that it requires fewer questions
than needed for the FRAX calculation. It should be noted,
however, that FRAX is not a tool for predicting vertebral
fractures, which may explain its inferior performance. The
reason we included it in our analysis is because it is likely
that calculation of FRAX will become a standard procedure
in densitometry, and we wanted to determine whether it
could also be used to decide who should have VFA testing.
In a recent report from a densitometry practice in the UK,
Middleton et al. also concluded that the selection of patients
for VFA should be based on a calculated index rather than
individual risk factors or BMD measurement [32].
Contrary to population studies which report lower
prevalence of vertebral fractures in men compared to
Table 4 Diagnostic utility of the Risk Factor Index (RFI) at two different cut-off points: sensitivity, specificity, and likelihood ratios (95%
confidence intervals); and positive and negative predictive values and corresponding post-test odds at different levels of vertebral fracture
prevalence
RFI≥2 RFI≥3
Sensitivity 93% (87, 96) 77% (69, 83)
Specificity 48% (45, 52) 76% (72, 79)
Likelihood ratio (+) 1.79 (1.6, 2.0) 3.13 (2.7, 3.7)
Likelihood ratio (−) 0.16 (0.09, 0.28) 0.31 (0.23, 0.42)
RFI≥2 RFI≥3
Prevalence of VFx 10% 15% 20% 10% 15% 20%
PPV (%) 16.6 24.0 30.9 25.8 35.6 43.9
(95% CI) (15.4, 17.8) (22.5, 25.7) (29.1, 32.8) (22.8, 29.0) (32.0, 39.4) (40.0, 47.9)
NPV (%) 98.3 97.3 96.3 96.7 94.8 92.8
(95% CI) (97.0, 99.0) (95.3, 98.5) (93.5, 97.9) (95.6, 97.5) (93.2, 96.1) (90.6, 94.6)
Pre-test odds (given) 0.111 0.176 0.25 0.111 0.176 0.25
Post-test odds (+) 0.199 0.316 0.448 0.348 0.553 0.783
(95% CI) (0.18, 0.22) (0.29, 0.35) (0.41, 0.49) (0.30, 0.41) (0.47, 0.65) (0.67, 0.92)
Post-test odds (−) 0.017 0.028 0.039 0.034 0.054 0.077
(95% CI) (0.03, 0.01) (0.05, 0.02) (0.07, 0.02) (0.05, 0.02) (0.07, 0.04) (0.10, 0.06)
Table 3 Odds ratio of having vertebral fracture(s) with increasing
age, decreasing BMD T-score, increasing height loss, or increasing
value of risk factor index
Risk factor OR (95% CI) p value
Age (compared to less than 60 years)
60–70 years 2.1 (0.9, 4.3) 0.054
70–80 years 3.2 (1.6, 6.7) 0.002
Over 80 years 7.5 (3.4, 16.5) <0.001
T-score WHO classification (vs. normal)
Osteopenia 2.3 (0.9, 5.5) 0.068
Osteoporosis 4.9 (2.1, 11.5) <0.001
T-score (compared to over −1)
Between −1 and −2 1.9 (0.7, 4.9) 0.190
Between −2 and −3 2.5 (1.0, 6.0) 0.045
Between −3 and −4 4.7 (1.9, 11.4) 0.001
Below −4 20.2 (7.5, 54.9) <0.001
Height loss (compared to <1 in.)
1–2 in. 1.7 (1.0, 2.8) 0.043
2–3 in. 2.6 (1.5, 4.4) 0.001
3–4 in. 7.5 (4.1, 13.9) <0.001
Over 4 in. 10.8 (5.2, 22.5) <0.001
Risk factor index
a (compared to <1)
1–2 5.7 (0.7, 45.1) 0.099
2–3 14.9 (2.0, 111.8) 0.009
3–4 35.8 (4.8, 266.4) <0.001
>4 190.0 (25.6, 1408) <0.001
OR odds ratio, 95% CI 95% confidence interval
aRisk factor index is derived using coefficients from a logistic
regression model which had vertebral fractures as outcome and all risk
factors from Table 1 as predictors
Osteoporos Int (2010) 21:2083–2091 2089women [16, 33], we found that males had higher
probability of having vertebral fractures relative to females
(Table 1). This is likely due to a referral bias, with men
undergoing bone densitometry if they have significant
pathology associated with osteoporosis, such as history of
glucocorticoid use or organ transplantation, while women
are referred for screening purposes. The prevalence of
vertebral fracture in our male subjects (34%) was very
similar to that reported in a study which examined VFA
results in men referred for BMD testing, where the
prevalence of vertebral fractures was 32% [34]. It is not
likely that the higher prevalence of vertebral fractures in
men was due to traumatic vertebral fractures because we
found a strong association between vertebral fractures and
low BMD T-scores, which would not be expected had the
vertebral fractures been of traumatic origin.
The model we derived is likely to perform well in
assessing the probability of finding vertebral fractures on
VFA in women referred for densitometry. This is supported
by our observation that the model we derived from two
thirds of subjects (randomized on main risk factors, see
Results) performed well in the remaining one third of
subjects. In addition, the values of regression coefficients
(odds ratio) from our model are similar to values reported
by Vogt [15] and Kaptoge [16], and the performance of our
model and that of Vogt and Kaptoge models in our study
population are very similar (data not shown). Nevertheless,
a further study in a different population may help to fully
test the predictive value of our model for its inclusion into
routine densitometry operation.
One could argue that VFA is not useful unless it impacts
the treatment decisions, which is most likely to occur in
subjects with BMD diagnosis of osteopenia. In practice,
however, many clinicians find information on vertebral
fractures useful even in patients who have osteoporosis by
BMD criteria. For example, in a treatment-naïve patient with
vertebral fractures, at least some experts would first use an
anabolic rather than an antiresorptive drug; a drug holiday
may not be offered after 5 years of bisphosphonate use to a
patient with vertebral fractures; or a patient who is reluctant
to use pharmacotherapy may be more likely to comply with
the treatment if vertebral fractures are discovered.
There are some limitations to our study. The number of
men in our study is too small to permit calculation of risk
factor score for men. However, inclusion of data from men
in our study is nevertheless important in that it illustrates
that men referred for densitometry have a higher probability
of having vertebral fractures than women. A second
possible limitation may be that we examined a convenience
sample rather than all 10,547 patients referred for densi-
tometry in our institution. Although there was no system-
atic bias, it is possible that the study population was more
“osteoporotic” because many of our study subjects were
clinic patients of the author (TJV), who has an osteoporosis
referral practice. While this may lower the generalizability
of our findings in terms of point estimation, the underlying
qualitative conclusions would be unlikely to change in a
lower risk population. The third possible limitation is that
we used a larger questionnaire, and thus a short version that
we propose for generating RFI was not directly tested.
However, the shorter questionnaire is, if anything, easier to
complete and more likely to be accurate. Finally, the best
use of a tool like this would be to incorporate it into the
densitometry software, which would require approval by
regulatory agencies. Although this may present an obstacle,
it is likely that if this general approach is accepted by the
medical community, the efforts to secure the approval may
be less difficult compared to approval of new devices or
new approaches such as FRAX. This is because VFA has
already been approved, is not associated with significant
risk to the patient, and because having a tool to help select
the patients for VFA testing is likely to ultimately improve
the cost-effectiveness of the procedure.
Our study also has significant strengths. It examined
the risk factors in patients undergoing densitometry rather
than in the general population and thus is better applicable
to densitometry in general. In addition, we examined
fractures detected by VFA and thus can provide informa-
tion that is pertinent to future use of this methodology
in contrast to earlier studies which used radiographs.
Finally, our study population is multiracial, which makes
our conclusions generalizable to broader populations than
previously studied.
In summary, we developed a decision-making tool,
which includes clinical risk factors and BMD measurement
to select patients for VFA imaging. The proposed model
could be incorporated into densitometry software to prompt
the technologist to perform VFA at the level of the risk
factor index which will be determined for each densitom-
etry center based on the expected prevalence of vertebral
fractures.
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